Navigation Links
Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
Date:7/23/2008

gational medicines, two of which are in late stages of clinical testing. Duska's ATPace(TM) is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward- looking statements to be covered by the safe harbor provisions for forward- looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that Duska believes that the proposed single, prospective, placebo-controlled, and randomized trial in patients presenting to the emergency room with paroxysmal supraventricular tachycardia (PSVT) should be sufficient to demonstrate clinical safety and efficacy, that Duska believes that upon successful completion of the proposed Phase 3 trial, it would have all the clinical data necessary to support the filing of the NDA for ATPace(TM) under section 505(b)(2), the belief tha
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
4. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
7. Organizational Changes at Silence Therapeutics
8. Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
9. Arno Therapeutics Announces New Ticker Symbol
10. Lorus Therapeutics Receives $600 Thousand From Escrow Account
11. Silence Therapeutics Announces Successful Opposition of Glover Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 PAREXEL International Corporation (NASDAQ: ... announced that Partnerships in Clinical Trials named PAREXEL,s ... Clinical Innovator of the Year.  The honor recognizes Mr. ... Company,s Perceptive MyTrials ® Data-Driven Monitoring solution. ... the 2015 Partnership Awards in Boston ...
(Date:4/23/2015)... 2015 The Thomas Brain Health ... a groundbreaking pilot study to see if early ... as little as three to six months. , ... nutritional medicine—will aggressively target and simultaneously treat the ... aging brain. These include oxidative stress, neuroinflammation, mitochondrial ...
(Date:4/23/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2015 results before the Nasdaq market opens on Thursday, ... call and webcast to discuss its financial results and ... at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... by dialing 866-952-1906 (US) or 785-424-1825 (International) using the ...
(Date:4/23/2015)... 2015  Veracyte, Inc. (NASDAQ: VCYT ) today ... to sell approximately $40 million of its common stock ... will purchase an aggregate of 4,907,975 shares of common ... the closing stock price on April 22, 2015. The ... including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners ...
Breaking Biology Technology:PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4
... Complete Genomics Inc.,a newly launched, third-generation human genome ... Annual BIO Investor Forum,which will be held in San ... president and chief executive officer of,Complete Genomics, will present ... Room of the Palace Hotel, located at 2 New ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today that ... Conference on October 28, 2008 at 2:00 p.m.,Pacific Time ... in La,Jolla, California. Jack Lief, Arena,s President and Chief ... company, including its,clinical development and discovery programs., A ...
... demonstrated that low dose sublingual Intermezzo(R), used at ... significantly shortened time to ... Oct. 22 Transcept,Pharmaceuticals, Inc., a privately-held specialty pharmaceutical ... safety and efficacy of,its lead product candidate, Intermezzo(R) (zolpidem ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 2Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 3Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 2Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 3Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 4Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 5Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 6
(Date:3/19/2015)... Conn. , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... in a news clip that aired this week on ... ) . In a segment "The Next Great ... wallet ,a new way to pay, and ,a really big ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/17/2015)... YORK , March 17, 2015  MecklerMedia ... the largest exhibition for service robots ever held ... RoboUniverse takes place on May 11-13, 2015 at ... and exhibitors for the event include: Acorn Product ... Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... Purdue University researchers are collaborating with Chrysler LLC in ... from a contaminated site in north-central Indiana. The ... a former oil storage facility near Kokomo, Ind., this ... been shown to be capable of absorbing trichloroethylene, or ...
... -- Rice University bioengineer Jennifer West is being recognized ... scientific honors, the O,Donnell Award from The Academy of ... O,Donnell Awards, given for excellence in medical, scientific and ... an inscribed statue. West, a pioneer in the field ...
... Ala. A drug originally used to treat iron ... heal and re-grow injured bones, according to researchers at ... researchers injected the drug deferoxamine (DF), which is designed ... found DF triggered the growth of new blood vessels, ...
Cached Biology News:Fighting pollution the poplar way: Trees to clean up Indiana site 2Fighting pollution the poplar way: Trees to clean up Indiana site 3Rice's West honored as one of Texas' best researchers 2Rice's West honored as one of Texas' best researchers 3New treatment boosts bone healing and regrowth 2
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... a modification of the procedure of ... 11 , 1055 (1969). ... an A 260 of 1.0 ... cm light path). Physical Form: lyophilized ...
Biology Products: